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BRCA1 and BRCA2 mutations have been associated with prostate cancer (PCa) risk but a wide range 
of risk estimates has been reported, based on retrospective studies.  
Objective 
To estimate relative and absolute PCa risks associated with BRCA1/2 mutations, and to assess risk-
modification by age, family history and mutation location. 
Design, Setting, and Participants 
Prospective cohort study of male BRCA1 (n=376) and BRCA2 carriers (n=447) identified through 
clinical genetics centres in the UK and Republic of Ireland (median follow-up: 5.9 and 5.3 yr, 
respectively).  
Outcome Measurements and Statistical Analysis  
Standardised incidence/mortality ratios (SIRs/SMRs) relative to population incidences or mortality 
rates, absolute risks and hazard ratios (HRs), estimated using cohort and survival analysis methods.  
Results and Limitations 
Sixteen BRCA1 and 26 BRCA2 carriers were diagnosed with PCa during follow-up. BRCA2 carriers had 
a SIR of 4.45 (95% confidence interval [CI] 2.99-6.61), and absolute PCa risk of 27% (95% CI 17%-
41%) and 60% (95% CI 43%-78%) by ages 75 and 85, respectively. For BRCA1 carriers, the overall SIR 
was 2.35 (95% CI 1.43-3.88); the corresponding SIR at ages<65 was 3.57 (95% CI 1.68-7.58). 
However, the BRCA1 SIR varied between 0.74 and 2.83 in sensitivity analyses to assess potential 
screening effects. PCa risks for BRCA2 carriers increased with family history (HR per affected 
relative=1.68, 95% CI 0.99-2.85). BRCA2 mutations in the region bounded by positions c.2831–c.6401 
were associated with an SIR of 2.46 (95% CI 1.07-5.64) compared to population incidences, 
corresponding to a lower PCa risk (HR=0.37, 95% CI 0.14-0.96) than for mutations outside the region. 
BRCA2 carriers had a stronger association with Gleason score≥7 (SIR=5.07, 95% CI 3.20-8.02) than 
Gleason score≤6 PCa (SIR=3.03, 95% CI 1.24-7.44), and increased risk of death from PCa (SMR=3.85, 
95% CI 1.44-10.3). Limitations include potential screening effects for these known mutation carriers; 
however, the BRCA2 results were robust to multiple sensitivity analyses. 
Conclusions 
The results substantiate PCa risk patterns indicated by retrospective analyses for BRCA2 carriers, 
including further evidence of association with aggressive PCa, and give some support for a weaker 
association in BRCA1 carriers.  
 
Patient Summary 
In this study we followed unaffected men who were known to carry mutations in the BRCA1 and 
BRCA2 genes, to investigate whether they are at higher risk of developing prostate cancer compared 





prostate cancer, particularly more aggressive prostate cancer, and that this risk varied by family 







Deleterious mutations in the tumour suppressor genes BRCA1 and BRCA2 are associated with high 
risks of breast and ovarian cancer [1,2], and have been implicated in the genetic susceptibility to 
prostate cancer (PCa). Retrospective studies have reported that BRCA2 mutations are associated 
with relative risks (RRs) of PCa in the range 2—6 [3–12]. RR estimates were reported to be higher at 
younger ages, in the range 6—9 below age 65 [3,5,12–14], and BRCA2 carriers present more often 
with aggressive PCa [7,8]. The evidence of association between BRCA1 mutations and PCa risk is 
inconsistent, with reported RRs in the range 0.4—4 [4,6–9,11,12,15–18]. A meta-analysis in 2011 
concluded that there is insufficient evidence for an association between BRCA1 mutations and PCa 
risk [19], but two studies have reported statistically significant RRs of 2—4 for BRCA1 carriers below 
age 65 [16,20]. Studies have also reported variation in PCa risks by mutation location or type 
[5,7,9,12,21,22]. 
 
There are only a few estimates of absolute risks of PCa for BRCA1/2 mutation carriers and those are 
based on retrospective studies [3,5,6,12,14,16,20,21]. Given the rapidly rising population PCa 
incidences in the PSA testing era, retrospective absolute risk estimates may not be representative of 
the risks for mutation carriers currently seen in genetics clinics. Only two small prospective cohort 
studies of male BRCA1/2 carriers have been reported [11,23], the largest of which followed 137 
BRCA1 and 71 BRCA2 carriers for an average of 5.1 yr, and did not show an association with PCa [23].  
 
In the present study, we report age-specific PCa risk estimates based on a large prospective cohort 
of male BRCA1 and BRCA2 carriers. We present relative and absolute risks, investigate variability in 
these risks by family history and mutation location, and consider the risk of developing high-grade 
PCa. 
 
Materials and Methods 
 
EMBRACE study participants 
 
The Epidemiological Study of Familial Breast Cancer (EMBRACE; 
http://ccge.medschl.cam.ac.uk/embrace/) is a cohort study of BRCA1 and BRCA2 mutation carriers 
initiated in 1998. Participants were recruited through clinical genetics centres across the UK and 
Republic of Ireland, and were counselled with regards to their mutation status. This analysis included 
all male participants without PCa diagnosis at recruitment who carried mutations considered to be 
pathogenic based on widely accepted criteria (ENIGMA consortium; 
https://enigmaconsortium.org/). All participants completed a baseline questionnaire which included 
information on known and suspected cancer risk factors, medical history and personal and family 
cancer history. Follow-up data were collected through linkage with national registers covering 
England, Wales and Scotland, and questionnaires collected two, five and ten yr post-baseline. For 
self-reported cancers, confirmation was sought from the participating clinics. For the present study, 





been reported at the time of the last record linkage (performed on 4th October 2016), or as the date 
of the last returned questionnaire if one was available after 30th June 2016. 
 
All participants provided written informed consent. The study was approved by the Anglia and 




We prospectively followed the participants from the completion of their baseline questionnaire until 
their age at diagnosis of PCa, age of death, age at the end-of-follow-up, or age 85, whichever 
occurred first. A diagnosis of another cancer or of prostatic intraepithelial neoplasia were not 
considered as censoring events. Analogously, we followed the participants for deaths due to PCa. 
 
We compared the observed PCa incidence and PCa mortality to that expected from population 
incidences and PCa-specific mortality rates (Office for National Statistics, https://www.ons.gov.uk/), 
using standardised incidence ratios (SIRs) or standardised mortality ratios (SMRs) computed with 
Poisson regression. We used the Kaplan—Meier estimator to estimate absolute risks, and Cox 
regression to test for differences in risk between subgroups.  
 
We classified men who had at least one first- or second-degree relative diagnosed with PCa as 
having positive PCa family history, and assessed trends in risks with the number of affected relatives. 
We investigated differences in risk by mutation position using pre-specified definitions of regions 
that have demonstrated different associations with PCa risk in published studies [5,9,12,21,22]. To 
assess the association of BRCA1/2 mutations with clinical PCa subtypes based on biopsy Gleason 
score (GS), we compared the observed number of PCa diagnoses by GS subtypes to those expected 
given population GS-specific incidences. We used competing risk estimators to estimate absolute 
risks of these clinical subtypes. Because data on GSs were not available for all PCas, we used multiple 
imputation to avoid omission of PCa events.  
 
For the main analysis, we included men with previous non-prostate cancers, did not censor for non-
prostate cancers during follow-up, and considered follow-up up to the last questionnaire if available 
after the last record linkage. We assessed the impact of these assumptions in sensitivity analyses. 
We also repeated the analysis after omitting pathogenic missense mutations to assess the impact of 
such less clearly deleterious mutations. 
 
Mutation carriers may be offered a different screening and diagnosis regimen than men in the 
general population [24]. We performed further analyses to assess the potential impact of such 
differential screening. First, we performed landmark analyses where follow-up was initiated six or 
twelve mo after baseline. Second, based on previous findings that observed PCa incidences are 1.4-





men [25], we estimated SIRs relative to population incidences multiplied by adjustment factors of 
1.6 and 1.9. To obtain absolute risk estimates, we used weighted Kaplan—Meier estimators. 
Furthermore, in October 2005 the UK-based IMPACT screening trial started recruiting BRCA1/2 
carriers [26]. Although the exact overlap between the studies is unclear, to investigate the impact on 
risk estimates we assessed PCa risks separately for participants from IMPACT-recruiting centres and 
their person-time from October 2005 and after; and, the person-time of participants from these 
centres before October 2005 in addition to the entire person-time of participants from non-IMPACT-
recruiting centres. 
 
Statistical analysis was performed using R (version 3.4.4) [27]. Full details of all methods are given in 






In total, 16 out of 376 BRCA1 and 26 out of 447 BRCA2 mutation carriers were diagnosed with PCa 
during a median follow-up of 5.9 and 5.3 yr, respectively (Table 1). All PCa diagnoses were either 
confirmed through registry linkage or through the participating clinics.  
 
Carrying a BRCA1 mutation was associated with a SIR of 2.35 (95% confidence interval [CI], 1.43-
3.88) of PCa relative to population incidences, whereas the SIR for BRCA2 carriers was 4.45 (95% CI 
2.99-6.61). For BRCA1 carriers, the SIR for ages<65 was 3.57 (95% CI 1.68-7.58) and the SIR for 
ages≥65 was 1.86 (95% CI 0.96-3.59). The SIR estimates by age were similar for BRCA2 carriers 
(ages<65: SIR=3.99, 95% CI 1.88-8.49; ages≥65: SIR=4.64, 95% CI 2.91-7.41). The estimated absolute 
risk of PCa was 21% (95% CI 13%-34%) by age 75 and 29% (95% CI 17%-45%) by age 85 for BRCA1 
carriers. The corresponding PCa risks for BRCA2 carriers were 27% (95% CI 17%-41%) and 60% (95% 
CI 43%-78%), respectively (Table 2; Figure 1A-B). 
 
For men with a positive family history, the SIRs were 3.17 (95% CI 0.97-10.37) for BRCA1 and 7.31 
(95% CI 3.40-15.72) for BRCA2 carriers. The corresponding SIRs for carriers without family history 
were 2.34 (95% CI 1.35-4.07) and 3.87 (95% CI 2.40-6.23), respectively. For BRCA2 carriers, the 
hazard ratio (HR) per affected relative was 1.68 (95% CI 0.99-2.85; Table 2; Figure 1C-D).  
 
Men with BRCA2 mutations located in the central region of the gene (c.2831–c.6401; ovarian cancer 
cluster region [OCCR], wide definition [2,21]; Supplementary appendix 1) were at significantly lower 
risk of PCa than men with mutations outside this region (HR=0.37, 95% CI 0.14-0.96). However, 
mutations both within (SIR=2.46, 95% CI 1.07-5.64) and outside (SIR=5.88, 95% CI 3.75-9.22) the 
OCCR were associated with elevated PCa risks. When BRCA2 mutations were grouped according to 
the narrow definition of the OCCR (c.3847–c.6275) [2,21] the difference in PCa risk for mutations 





hazards assumption was violated for this model (Schoenfeld residuals test, p=0.005); the 
corresponding Kaplan—Meier curves revealed that the risks were similar between the OCCR and 
non-OCCR mutation carriers at younger ages but deviated at older ages (Figure 1E-F). The difference 
in risk between OCCR and non-OCCR mutation carriers (wide definition) was not statistically 
significant but of similar magnitude after adjusting for family history (adjusted HR=0.40, 95% CI 0.15-
1.07) and after omitting Ashkenazi mutation carriers (HR=0.43, 95% CI 0.15-1.24; Table 3).  
 
Gleason-score-specific prostate cancer  
 
For BRCA1 carriers, the SIR was higher for GS≤6 (SIR=3.50, 95% CI 1.67-7.35) than GS≥7 PCa 
(SIR=1.80, 95% CI 0.89-3.65). In contrast, for BRCA2 carriers the SIR was higher for GS≥7 (SIR=5.07, 
95% CI 3.20-8.02) than GS≤6 PCa (SIR=3.03, 95% CI 1.24-7.44; Table 4). By age 85, the absolute risks 
for GS≤6 and GS≥7 PCa were 12% (95% CI 5.0%-23%) and 16% (95% CI 6.4%-30%) for BRCA1, and 
9.3% (95% CI 2.9%-20%) and 51% (95% CI 30%-69%) for BRCA2 carriers, respectively. 
 
Prostate cancer mortality 
 
Two BRCA1 and four BRCA2 carriers died from their incident PCa during the follow-up. Compared to 
population PCa-specific mortality rates, the SMR was 1.75 (95% CI 0.44-6.90) for BRCA1 and 3.85 




The estimated SIRs remained similar under alternative inclusion or censoring assumptions (Table 5). 
Of the 42 diagnoses of PCa, nine occurred within the first six mo after study entry (Supplementary 
table 1). In the landmark analyses, where follow-up was initiated six or twelve mo after study entry, 
SIRs were lower for both BRCA1 (six-month landmark: SIR=2.02, 95% CI 1.17-3.50; twelve-month 
landmark: SIR=2.15, 95% CI 1.24-3.73) and BRCA2 carriers (six-month landmark: SIR=3.68, 95% CI 
2.35-5.75; twelve-month landmark: SIR=3.37, 95% CI 2.08-5.47) but remained statistically significant. 
In the six-month landmark analysis, the estimated absolute PCa risk by age 85 was 26% (95% CI 15%-
43%) for BRCA1 and 55% (95% CI 36%-75%) for BRCA2 carriers. When compared to a hypothetical 
population with higher PCa incidence, the association remained significant for BRCA2 carriers 
(adjustment factor 1.9: SIR=2.34, 95% CI 1.57-3.48). The overall association was not significant for 
BRCA1 carriers (adjustment factor 1.9: SIR=1.24, 95% CI 0.75-2.04), but the association for ages<65 
remained significant with the lower, 1.6 adjustment factor (SIR=2.23, 95% CI 1.05-4.73). The 
corresponding absolute risk by age 85 when adjusted by a factor of 1.9, was 17% (95% CI 8%-26%) 
for BRCA1 and 41% (95% CI 22%-59%) for BRCA2 mutation carriers. When the landmark analysis was 
applied assuming higher population incidences, only the overall association between BRCA2 






When follow-up was restricted to the period prior to the initiation of the IMPACT screening trial [26], 
in addition to the entire follow-up of participants from non-IMPACT-recruiting centres, there was no 
association with PCa risk for BRCA1 carriers (SIR=0.74, 95% CI 0.18-3.04). This was however based on 
a small sample size and the 95% CI overlapped with that of the estimate for BRCA1 carriers from 
IMPACT-recruiting centres with follow-up after October 2005 (SIR=2.83, 95% CI 1.67-4.81). The point 
estimates were similar for BRCA2 carriers followed without potential overlap with the IMPACT trial 
period and recruiting centres (SIR=3.57, 95% CI 1.29-9.85) and those whose follow-up potentially 
overlapped with IMPACT (SIR=4.54, 95% CI 2.96-6.99). The SIR for ages<65 for BRCA2 carriers with 
no potential overlap with IMPACT was 6.75 (95% CI 1.98-23.0; Table 5).  
 
When follow-up was initiated six mo after baseline, the SIRs for BRCA1 carriers were similar for GS≤6 
(SIR=2.26, 95% CI 0.86-5.91) and GS≥7 PCa (SIR=1.90, 95% CI 0.93-3.85), in contrast to the main 
results. However, the difference in the GS-specific SIR estimates remained for BRCA2 carriers (GS≤6: 
SIR=2.01, 95% CI 0.60-6.80; GS≥7: SIR=4.39, 95% CI 2.63-7.31; Table 4). Based on this analysis, the 
absolute risks by age 85 for BRCA1 carriers were 7.8% (95% CI 2.2%-18%) for GS≤6 and 18% (95% CI 
7.1%-33%) for GS≥7 PCa. For BRCA2 carriers the corresponding risks were 7.1% (95% CI 1.4%-19%) 




We have estimated the risks of PCa for male BRCA1 and BRCA2 mutation carriers using data from a 
large prospective cohort. The results substantiate previous reports from retrospective studies of a 
strong association between BRCA2 mutations and PCa risk, and give some support for a similar but 
weaker association for mutations in the BRCA1 gene, particularly at younger ages.   
 
Depending on assumptions, we found that BRCA2 carriers are at 2—5 times higher risk of PCa 
compared to men in the general population, which is consistent with previous RR estimates in the 
range 2—6 [3–12]. Our BRCA2 RR estimates did not vary substantially with age, in contrast with 
previous studies which suggest higher RRs at younger ages [3,5,12–14]. However, the higher RR 
estimate at ages<65 for the subset of BRCA2 carriers with no potential overlap with the IMPACT 
screening trial suggests that the similarities in the associations by age might be due to potential 
screening effects. Due to the small number of events at younger ages the precision of the estimates 
was however low. In line with previous studies [4,6–9,11,12,15–18,20], our findings indicate that 
BRCA1 mutations are at most associated with a moderate PCa risk at younger ages, with RR 
estimates in the range 2—4 for ages below 65 yr. The evidence of association is weak at older ages, 
with our RR estimates varying between 1—2. Much larger studies are required to clarify the 
association between BRCA1 mutations and PCa risk.  
 
The estimated cumulative risk of developing PCa by age 85 was 29% (95% CI 17%-45%) for BRCA1 
and 60% (95% CI 43%-78%) for BRCA2 carriers. However, absolute PCa risks depend on the 
employed screening regimen, and the PCa risks were lower in analyses that assessed the impact of 
potentially prevalent cancers and the excess PCa risk in PSA-screened individuals. Although our RR 





higher compared to estimates from retrospective studies. Previous absolute PCa risk estimates by 
ages 65 to 80 range from 3%—9% for BRCA1 carriers [6,16,20] and 15%—34% for BRCA2 carriers 
(Supplementary table 2) [3,5,6,12,14,21]. It is plausible that absolute risk estimates based on 
historical data are not representative of the absolute PCa risks for BRCA1/2 carriers in the PSA 
testing era. Prospective risk estimates may be more informative for counselling current mutation 
carriers. Only two previous prospective studies on PCa risk for male BRCA1/2 carriers have been 
reported but were limited by small sample sizes and wide CIs for their RR estimates, and neither 
presented absolute risk estimates. In a prospective cohort of 62 carriers from the US, BRCA2 
mutations were associated with increased PCa risk (SIR=4.89, 95% CI 1.96-10.08) but there was no 
significant association for BRCA1 carriers (SIR=3.81, 95% CI 0.77-11.13) [11]. An Israeli study 
observed only three prospective PCas in 210 unaffected BRCA1/2 carriers (median follow-up: 5.1 yr) 
and chose not to report a prospective RR estimate [23].  
 
The results indicate that PCa risks for mutation carriers increase with the number of affected 
relatives, consistent with findings in the general population [28]. This is also consistent with the 
hypothesis that other familial factors modify PCa risks for mutation carriers, and with recent 
observations that common PCa susceptibility genetic variants [29] modify PCa risks for BRCA1/2 
carriers [30]. This emphasises the importance of considering family history and other risk-modifying 
genetic factors when counselling male BRCA1/2 carriers. However, it is possible that mutation 
carriers with family history of PCa are more likely to be screened or biopsied than mutation carriers 
without a PCa family history; this may also partly explain the higher observed risk. 
 
We found BRCA1 carriers to be at higher risk of GS≤6 disease, but after omitting diagnoses in the 
initial six mo after study recruitment, the associations with high- and low-grade disease were similar. 
BRCA1 carriers were not at significantly increased risk of PCa mortality, though the CI of the SMR 
estimate was wide. A lack of association between BRCA1 mutations and PCa grade is in line with 
published data [7,8], and the higher SIR for GS≤6 disease might reflect a higher propensity for 
diagnosing indolent low-grade tumours that would not have been detected in the absence of the 
discovery of a deleterious mutation. Conversely, our results suggest that BRCA2 mutations are 
associated with a more aggressive PCa phenotype: the association was stronger with GS≥7 than 
GS≤6 tumours. Furthermore, we observed a significant association between BRCA2 mutations and 
PCa mortality. Associations with high-grade disease and PCa mortality is consistent with previous 
reports for BRCA2 carriers [7,8], and suggests that the BRCA2 findings are less affected by screening 
effects. 
 
BRCA2 mutations both within and outside the OCCR were associated with elevated PCa risks. 
However, our results suggest that carriers of mutations within the OCCR are at comparatively lower 
risk than carriers of mutations outside the OCCR, consistent with previous findings [5,21]. It is also 
consistent with reports of lower PCa risks for carriers of the BRCA2 c.5946delT Ashkenazi Jewish 
founder mutation, which is located in the OCCR [22]. The results however contrast with a UK study 
which reported an HR of 2.92 (95% CI 1.54-5.54) for OCCR compared to non-OCCR mutations [9]. 
However, this study was based on a retrospective cohort of BRCA2 carriers and their relatives and 






Strengths of the study include the nationwide recruitment of mutation carriers, which supports the 
generalisability of our findings. Furthermore, this is the largest prospective cohort of men with 
deleterious BRCA1/2 mutations to date, and the prospective study-design allows for direct 
estimation of both relative and absolute risks. We have provided risk estimates by family history and 
mutation location.  
 
Despite our study being the largest prospective study to report to date, the precision of our 
estimates is still limited by a moderate sample size and number of incident PCas and PCa deaths. The 
results by GS are limited by potential inaccuracies in tumour grading based on biopsies; however, 
since mutation carriers were recruited through a UK-wide study and SIRs were computed relative to 
national GS-specific incidences (which will have similar inaccuracies), variability in pathological 
grading is unlikely to have resulted in a systematic bias. Other limitations include a possible 
oversampling of men with a family history of PCa, as a result of the recruitment through clinical 
genetics centres. While this allowed us to obtain estimates applicable to mutation carriers both with 
and without family history, the overall risk might be somewhat overestimated compared to the 
average BRCA1/2 carrier in the population. In addition, known mutation carriers who undergo 
genetic counselling may receive enhanced screening compared to men from the general population. 
More specifically, during the study period, the IMPACT screening trial [26] also recruited male 
BRCA1/2 carriers, and therefore some overlap between IMPACT and EMBRACE is likely. Given the 
background prevalence of indolent PCas that are undetectable in the absence of screening [31] and 
our observed clustering of PCa diagnoses shortly after study entry, it is plausible that some of these 
PCas would not have been discovered in the absence of diagnostic measures taken as a result of the 
discovery of a mutation. When we initiated follow-up six or twelve mo after study entry the 
estimated RRs were attenuated for both BRCA1 and BRCA2 carriers, but remained statistically 
significant. Furthermore, known mutation carriers may be subjected to a different screening 
regimen over an extended period of time as compared to men in the general population [24]. To 
assess this we compared the observed PCa incidence to that expected from population incidences 
adjusted by screening effect sizes estimated in the ERSPC trial [25]. The SIRs for BRCA2 carriers 
remained significant, but the excess risk for BRCA1 carriers was not consistently significant, and was 
significant only for ages below 65. This adjustment is limited by the assumption of a constant 
average screening effect on the population PCa incidences, based on the published estimates by 
ERSPC [25]. The ERSPC data also suggest that the effect of screening may be time-dependent with a 
probable decrease in screening effect sizes with time since initiation of screening [25]. This time-
dependency was not considered in this analysis and can result in a potential overestimation of SIRs, 
if the true effect of screening on population incidences is higher than the assumed average during 
the follow-up period. However, our adjustment used the highest published average PSA screening 
effect size from ERSPC, and assumes that no screening occurs in the general population, which is 
unlikely given the rates of opportunistic screening [32] and may result in an attenuation of the SIR 
estimates. After using both a six-month landmark to control for the detection of prevalent PCas, and 
higher population incidences, the SIRs remained significant only for BRCA2 carriers. These may 
however represent extreme over-adjustments. Finally, when we restricted the follow-up to 
recruiting centres and/or time-periods not overlapping with the recruitment to the IMPACT trial, we 
found no association between BRCA1 mutations and PCa risk. This might suggest that the observed 
association for BRCA1 carriers is driven by screening-induced diagnoses of indolent tumours, but 
caution is needed in the interpretation as the sample size used for this subgroup analysis was small. 
In contrast, the strength of association was similar for BRCA2 carriers regardless of the potential 





regardless of screening regimen, this observation is consistent with the hypothesis that BRCA2 
mutations are associated with risk of more aggressive disease. It provides further evidence that the 




This prospective analysis has substantiated previous reports on the RRs of PCa for BRCA1 and BRCA2 
mutation carriers from retrospective studies, and has provided direct estimates of absolute PCa risks 
by family history and mutation characteristics. The results will be informative in the counselling of 
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Figure and Table legends 
 
Figure 1: Absolute prostate cancer risks for BRCA1 and BRCA2 mutation carriers, with the number at 
risk at each age on the x-axis.  
A: Overall.  
B: Overall, with follow-up initiated six mo after study entry.  
C: By family history.  
D: By family history, with follow-up initiated six mo after study entry.  
E: By the BRCA2 ovarian cancer cluster region (OCCR, wide definition) [2,21].  
F: By the BRCA2 ovarian cancer cluster region (OCCR, wide definition) [2,21], with follow-up initiated 
six mo after study entry. 
Family history was defined as having at least one first- or second-degree relative with a prostate 
cancer diagnosis at the time of study entry. 
 
Table 1: Participant characteristics. 
 
Table 2: Standardised incidence ratios and absolute risks of prostate cancer for BRCA1 and BRCA2 
mutation carriers, overall and by age and family history.  
 
Table 3: Standardised incidence ratios and absolute risks of prostate cancer for BRCA2 mutation 
carriers, by location of the mutation within the BRCA2 gene.  
 
Table 4: Gleason-score specific standardised incidence ratios of prostate cancer for BRCA1 and 
BRCA2 mutation carriers. 
 
Table 5: Sensitivity analyses. 
 
Supplementary appendix 1: Full details on the statistical analysis. 
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Table 1: Participant characteristics. 
Initially recruited 998 
 Excluded: mutation in both BRCA1 and BRCA2 4 
  BRCA1 carriers BRCA2 carriers 
Initially recruited 451 543 
 Excluded: variant of unknown significance 3 3 
 Excluded: previous prostate cancer diagnosis 14 37 
 Excluded: age≥85 at baseline 1 0 
 Excluded: no follow-up beyond baseline 57 56 
Included N=376a N=447a  
  
Characteristics n (%) n (%) 
Year of study entry     
 1999
b-2004 69 (18%) 48 (11%) 
 2005-2010 144 (38%) 172 (38%) 
 2011-2016 163 (43%) 227 (51%) 
Age at study entry, years     
 Median [inter-quartile range] 54.0 [43.2-64.1] 51.4 [41.5-63.6] 
 19-44 103 (27%) 155 (35%) 
 45-54 97 (26%) 105 (23%) 
 55-64 96 (26%) 102 (23%) 
 65-74 65 (17%) 66 (15%) 
 75-83 15 (4.0%) 19 (4.3%) 
Follow-up timec, years     
 Median [inter-quartile range] 5.9 [3.0-10.1] 5.3 [2.6-8.9] 
Family history of prostate cancerd     
 No 297 (79%) 328 (73%) 
 Yes 48 (13%) 87 (19%) 
 
Unknown: At least one male relative with 
unknown cancer site 14 (3.7%) 16 (3.6%) 
 Missing data 17 (4.5%) 16 (3.6%) 
Previous non-prostate cancer diagnosis     
 No 355 (94%) 390 (87%) 
 Yes 21
e (5.6%) 57e (13%) 
Non-prostate cancer diagnosis during follow-up     
 No 349 (93%) 429
f (96%) 
  Yes 27g (7.2%) 18g (4.0%) 
Prostate cancer diagnosis     
  n=16 n=26 
Age at prostate cancer diagnosis, years     
 Median [inter-quartile range] 66.0 [61.9-71.7] 71.4 [62.8-77.5] 
Diagnostic modality     
 Screening 11 (69%) 14 (54%) 
 Clinical symptoms 3 (19%) 7 (27%) 





PSA at diagnosis, ng/mL     
 Median [inter-quartile range] 5.0 [3.6-5.9] 6.2 [4.3-21.6] 
Clinical stage     
 T1 1 (6.3%) 4 (15%) 
 T2 7 (44%) 12 (46%) 
 T3 4 (25%) 2 (7.7%) 
 T4 0 (0%) 1 (3.8%) 
 TX 1 (6.3%) 1 (3.8%) 
 Missing data 3 (19%) 6 (23%) 
Gleason score     
 ≤6 7 (44%) 4 (15%) 
 3+4 4 (25%) 7 (27%) 
 4+3 0 (0%) 3 (12%) 
 ≥8 2 (13%) 5 (19%) 
  Missing data 3 (19%) 7 (27%) 
 
a BRCA1: 309 singletons, 23 families with two relatives, 4 families with three relatives, 1 family with four 
relatives, 1 family with five relatives.  
BRCA2: 353 singletons, 36 families with two relatives, 6 families with three relatives, 1 family with four 
relatives. 
b Study recruitment was initiated in August 1998 but the first male participant was recruited in February 1999. 
c Calculated using the reverse Kaplan-Meier method. 
d At least one first- or second-degree relative diagnosed with prostate cancer. 
e Includes 4 BRCA1 and 35 BRCA2 carriers with male breast cancer. 
f Includes 3 BRCA2 carriers who were diagnosed with high-grade prostatic intraepithelial neoplasia and who 
did not develop any malignant tumours. 
g Includes 1 BRCA1 and 2 BRCA2 carriers with male breast cancer, and 2 BRCA1 and 3 BRCA2 carriers with 
pancreatic cancer. 





Table 2: Standardised incidence ratios and absolute risks of prostate cancer for BRCA1 and BRCA2 mutation carriers, overall and by age and family history.  





Incidence rate per 1000 
person-years (95% CI) 
Expected 
events SIR (95% CI) 
Kaplan-Meier cumulative 
prostate cancer riska (95% CI) 
Overall 
BRCA1 Age 19-44 103 510.0 0 0.00  0.00 0.00  0%  
 Age 45-54 134 556.0 2 3.60 (0.90-14.4) 0.21 9.56 (2.39-38.2) 3.5% (0.87%-13%) 
 Age 55-64 162 707.3 5 7.07 (2.92-17.1) 1.75 2.86 (1.18-6.94) 9.9% (4.8%-20%) 
 Age 65-74 138 539.1 7 13.0 (6.15-27.4) 3.32 2.11 (1.00-4.46) 21% (13%-34%) 
 Age 75-84 53 192.9 2 10.4 (2.57-41.9) 1.51 1.32 (0.33-5.33) 29% (17%-45%) 
 Age 19-64 296 1773.3 7 3.95 (1.88-8.31) 1.96 3.57 (1.68-7.58) 10% (4.8%-20%) 
 Age 65-84 153 731.9 9 12.3 (6.39-23.7) 4.84 1.86 (0.96-3.59) 29% (17%-45%) 
 Overall 376 2505.3 16 6.39 (3.91-10.4) 6.80 2.35 (1.43-3.88) 29% (17%-45%) 
BRCA2 Age 19-44 155 622.9 0 0.00  0.01 0.00  0%  
 Age 45-54 173 720.1 4 5.56 (2.05-15.0) 0.27 14.7 (5.43-39.8) 5.4% (2.1%-14%) 
 Age 55-64 171 593.2 3 5.06 (1.63-15.7) 1.47 2.04 (0.65-6.36) 10% (5.0%-21%) 
 Age 65-74 134 463.3 9 19.4 (9.93-38.0) 2.88 3.13 (1.60-6.12) 27% (17%-41%) 
 Age 75-84 51 155.0 10 64.5 (33.2-125.4) 1.21 8.25 (4.25-16.0) 60% (43%-78%) 
 Age 19-64 362 1936.2 7 3.62 (1.71-7.65) 1.75 3.99 (1.88-8.49) 10% (5.0%-21%) 
 Age 65-84 153 618.2 19 30.7 (19.3-49.0) 4.09 4.64 (2.91-7.41) 60% (43%-78%) 
 Overall 447 2554.4 26 10.2 (6.92-15.0) 5.85 4.45 (2.99-6.61) 60% (43%-78%) 
By family history of prostate cancerb 
BRCA1 No family history 311 2110.0 13 6.16 (3.58-10.6) 5.55 2.34 (1.35-4.07) 31% (17%-50%) 
 Family history 48 264.8 3 11.3 (3.54-36.3) 0.95 3.17 (0.97-10.4)c 28% (9.8%-64%) 
BRCA2 No family history 344 1969.9 18 9.14 (5.75-14.5) 4.65 3.87 (2.40-6.23) 47% (31%-65%) 







CI: confidence interval. SIR: standardised incidence ratio. HR: hazard ratio. 
a Estimated cumulative prostate cancer risk by the end of each age interval, or age 85. 
b At least one first- or second-degree relative diagnosed with prostate cancer. 
c BRCA1 carriers: HR per affected first- or second-degree relative = 1.33 (95% CI 0.42-4.20). 
d BRCA2 carriers: HR per affected first- or second-degree relative = 1.68 (95% CI 0.99-2.85). 
e Age 85 prostate cancer risk estimate not available due to a low number of individuals left in the follow-up. At age 75, the cumulative PCa risk estimate was 43% (18%-
80%) for BRCA2 carriers with family history and 22% (12%-36%) for BRCA2 carriers without family history. 





Table 3: Standardised incidence ratios and absolute risks of prostate cancer for BRCA2 mutation carriers, by location of the mutation within the BRCA2 gene.  









events SIR (95% CI) 
Kaplan-Meier 
cumulative PCa 
riska (95% CI) HR (95% CI) 
HR adjusted for family 





BRCA2 Ovarian cancer cluster region (OCCR), wide definition [2,21] 
5' to c.2830 or 
c.6402 to 3' 
(Non-OCCR) 267 1489.2 20 13.4 (8.64-20.9) 3.40 5.88 (3.75-9.22) 
11% (4.3%-28%) 
Reference Reference Reference 
30% (17%-49%) 
83% (61%-96%) 
c.2831 to c.6401 
(OCCR) 178 1054.4 6 5.69 (2.54-12.8) 2.44 2.46 (1.07-5.64) 
10% (3.4%-29%) 
0.37 (0.14-0.96) 0.40 (0.15-1.07) 0.43 (0.15-1.24) 
22% (11%-43%) 
22% (11%-43%) 
Indeterminable 2                
BRCA2 Ovarian cancer cluster region (OCCR), narrow definition [2,21]  
5' to c.3846 or 
c.6276 to 3' 
(Non-OCCR) 284 1581.8 20 12.6 (8.14-19.7) 3.56 5.62 (3.59-8.81) 
10% (4.0%-26%) 
Reference Reference Reference 
29% (16%-48%) 
80% (59%-94%) 
c.3847 to c.6275 
(OCCR) 161 961.8 6 6.24 (2.78-14.0) 2.28 2.63 (1.14-6.04) 
11% (3.7%-31%) 
0.42 (0.16-1.09) 0.46 (0.17-1.22) 0.50 (0.17-1.45) 
23% (11%-45%) 
23% (11%-45%) 
Indeterminable 2                
BRCA2 Prostate cancer cluster region (PCCR) [12] 
5' to c.6372 or 
c.6493 to 3' 
(Non-PCCR) 444 2540.0 26 10.2 (6.95-15.1) 5.83 4.46 (3.00-6.64) 
10% (5.0%-21%) 
Reference     
27% (17%-41%) 
61% (43%-79%) 
c.6373 to c.6492 
(PCCR) 3 14.4 0 0.00  0.02 0.00  
0%  





CI: confidence interval. SIR: standardised incidence ratio. HR: hazard ratio. 
a Estimated cumulative prostate cancer risk by ages 65, 75 and 85, respectively. 
b Carriers of c.5946delT. 






















Multiple imputations and 
six-month landmark 
SIR (95% CI) SIR (95% CI) SIR (95% CI) 
BRCA1 373 2488.9 3                   
    ≤6 7 2.19 3.25 (1.54-6.88) 3.50 (1.67-7.35) 2.26 (0.86-5.91) 
        ≥7 6 4.61 1.32 (0.59-2.98) 1.80 (0.89-3.65) 1.90 (0.93-3.85) 
BRCA2 440 2537.4 7                   
    ≤6 4 1.83 2.23 (0.83-5.97) 3.03 (1.24-7.44) 2.01 (0.60-6.80) 
        ≥7 15 4.02 3.80 (2.27-6.38) 5.07 (3.20-8.02) 4.39 (2.63-7.31) 
 
Abbreviations 
CI: confidence interval. SIR: standardised incidence ratio. 
a Pooled estimates from 100 imputations using Multivariate Imputation by Chained Equations. The following covariates were used for the imputation: Prostate cancer status, Gleason score, 
PSA at diagnosis, Clinical stage, Diagnostic modality (screening/clinical), Mutation gene (BRCA1/2), Year of birth, Age at study entry, Age at follow-up, Family history (number of affected first- 
and second-degree relatives). 





Table 5: Sensitivity analyses. 





Events per 1000 person-
years (95% CI) 
Expected 
events SIR (95% CI) 
Kaplan-Meier cumulative 
PCa riska (95% CI) 
Excluding men with 
previous non-
prostate cancers 
BRCA1 Age 19-64 286 1724.5 7 4.06 (1.91-8.61) 1.90 3.68 (1.73-7.81) 10% (5.0%-20%) 
 Age 65-84 141 659.6 9 13.6 (7.09-26.2) 4.32 2.08 (1.08-4.01) 32% (19%-50%) 
 Overall 355 2384.1 16 6.71 (4.09-11.0) 6.23 2.57 (1.56-4.23) 32% (19%-50%) 
BRCA2 Age 19-64 342 1859.8 7 3.76 (1.78-7.96) 1.62 4.32 (2.03-9.21) 11% (5.3%-22%) 
 Age 65-84 110 454.0 11 24.2 (13.3-44.3) 2.95 3.72 (2.03-6.82) 60% (34%-87%) 
  Overall 390 2313.8 18 7.78 (4.90-12.4) 4.57 3.94 (2.45-6.32) 60% (34%-87%) 
Censoring for non-
prostate cancers in 
the follow-up 
BRCA1 Age 19-64 296 1740.9 7 4.02 (1.91-8.46) 1.90 3.68 (1.74-7.81) 10% (5.0%-20%) 
 Age 65-84 151 684.5 9 13.1 (6.84-25.3) 4.51 2.00 (1.04-3.85) 30% (18%-48%) 
 Overall 376 2425.4 16 6.60 (4.04-10.8) 6.41 2.50 (1.52-4.11) 30% (18%-48%) 
BRCA2 Age 19-64 362 1919.4 7 3.65 (1.72-7.71) 1.73 4.06 (1.91-8.63) 10% (5.1%-21%) 
 Age 65-84 150 599.8 18 30.0 (18.6-48.5) 3.97 4.53 (2.80-7.32) 59% (42%-78%) 
  Overall 447 2519.2 25 9.92 (6.69-14.7) 5.70 4.39 (2.93-6.57) 59% (42%-78%) 
Censoring all on 30th 
June 2016 
BRCA1 Age 19-64 296 1751.7 7 4.00 (1.90-8.41) 1.92 3.64 (1.72-7.72) 10% (4.9%-20%) 
 Age 65-84 148 713.0 8 11.2 (5.62-22.4) 4.71 1.70 (0.85-3.40) 28% (17%-44%) 
 Overall 376 2464.7 15 6.09 (3.67-10.1) 6.64 2.26 (1.35-3.78) 28% (17%-44%) 
BRCA2 Age 19-64 362 1895.7 7 3.69 (1.75-7.81) 1.71 4.10 (1.93-8.74) 10% (5.1%-21%) 
 Age 65-84 153 599.7 19 31.7 (19.9-50.6) 3.97 4.79 (3.00-7.65) 61% (43%-79%) 
  Overall 447 2495.4 26 10.4 (7.08-15.3) 5.67 4.58 (3.08-6.82) 61% (43%-79%) 
Excluding missense 
mutation carriers 
BRCA1 Age 19-64 288 1741.0 7 4.02 (1.91-8.46) 1.94 3.61 (1.70-7.65) 10% (4.9%-20%) 
 Age 65-84 152 721.5 9 12.5 (6.48-24.0) 4.77 1.89 (0.98-3.64) 29% (18%-45%) 
 Overall 368 2462.5 16 6.50 (3.97-10.6) 6.71 2.38 (1.45-3.93) 29% (18%-45%) 
BRCA2 Age 19-64 358 1924.2 7 3.64 (1.72-7.69) 1.75 4.00 (1.88-8.50) 10% (5.0%-21%) 
 Age 65-84 148 593.8 18 30.3 (18.8-48.9) 3.91 4.60 (2.85-7.43) 61% (43%-79%) 
  Overall 438 2517.9 25 9.93 (6.69-14.7) 5.67 4.41 (2.94-6.61) 61% (43%-79%) 








 Age 65-84 134 623.6 7 11.2 (5.34-23.6) 4.14 1.69 (0.80-3.56) 27% (15%-47%) 
 Overall 332 2159.3 12 5.56 (3.15-9.81) 5.78 2.08 (1.17-3.68) 27% (15%-47%) 
BRCA2 Age 19-64 330 1769.3 6 3.39 (1.51-7.62) 1.55 3.86 (1.71-8.72) 9.8% (4.5%-21%) 
 Age 65-84 136 533.0 19 35.6 (22.3-57.0) 3.53 5.38 (3.36-8.60) 65% (46%-83%) 
  Overall 405 2302.4 25 10.9 (7.32-16.1) 5.09 4.91 (3.28-7.36) 65% (46%-83%) 
Follow-up initiated 6 
months after baseline 
BRCA1 Age 19-64 268 1631.6 5 3.06 (1.27-7.42) 1.84 2.72 (1.12-6.58) 7.3% (3.1%-17%) 
 Age 65-84 149 691.7 8 11.6 (5.79-23.1) 4.59 1.74 (0.87-3.49) 26% (15%-43%) 
 Overall 352 2323.3 13 5.60 (3.24-9.68) 6.43 2.02 (1.17-3.50) 26% (15%-43%) 
BRCA2 Age 19-64 335 1761.7 5 2.84 (1.17-6.87) 1.61 3.10 (1.28-7.54) 8.5% (3.6%-19%) 
 Age 65-84 141 577.2 15 26.0 (15.5-43.7) 3.83 3.92 (2.33-6.60) 55% (36%-75%) 
  Overall 414 2338.8 20 8.55 (5.51-13.3) 5.44 3.68 (2.35-5.75) 55% (36%-75%) 
Follow-up initiated 12 
months after baseline 
BRCA1 Age 19-64 256 1500.4 5 3.33 (1.37-8.09) 1.73 2.89 (1.19-7.02) 7.8% (3.3%-18%) 
 Age 65-84 144 650.3 8 12.3 (6.14-24.6) 4.33 1.85 (0.92-3.71) 27% (15%-45%) 
 Overall 341 2150.7 13 6.04 (3.49-10.5) 6.06 2.15 (1.24-3.73) 27% (15%-45%) 
BRCA2 Age 19-64 313 1600.4 5 3.12 (1.29-7.57) 1.49 3.37 (1.38-8.21) 8.9% (3.8%-20%) 
 Age 65-84 136 535.7 12 22.4 (12.6-39.8) 3.56 3.37 (1.89-6.00) 51% (31%-74%) 
  Overall 400 2136.1 17 7.96 (4.95-12.8) 5.05 3.37 (2.08-5.47) 51% (31%-74%) 
Comparison to 
population incidences 
increased by a factor 
of ×1.6 [25]c 
BRCA1 Age 19-64 296 1773.3 7 3.95 (1.88-8.31) 3.14 2.23 (1.05-4.73) 6.3% (1.6%-11%) 
 Age 65-84 153 731.9 9 12.3 (6.39-23.7) 7.74 1.16 (0.60-2.24) 19% (8.8%-30%) 
 Overall 376 2505.3 16 6.39 (3.91-10.4) 10.9 1.47 (0.89-2.42) 19% (8.8%-30%) 
BRCA2 Age 19-64 362 1936.2 7 3.62 (1.71-7.65) 2.81 2.49 (1.17-5.31) 6.6% (1.7%-11%) 
 Age 65-84 153 618.2 19 30.7 (19.3-49.0) 6.55 2.90 (1.82-4.63) 46% (27%-65%) 
  Overall 447 2554.4 26 10.2 (6.92-15.0) 9.35 2.78 (1.87-4.13) 46% (27%-65%) 
Comparison to 
population incidences 
increased by a factor 
of ×1.9 [25]c 
BRCA1 Age 19-64 296 1773.3 7 3.95 (1.88-8.31) 3.72 1.88 (0.89-3.99) 5.4% (1.6%-9.3%) 
 Age 65-84 153 731.9 9 12.3 (6.39-23.7) 9.19 0.98 (0.51-1.89) 17% (8.0%-26%) 
 Overall 376 2505.3 16 6.39 (3.91-10.4) 12.9 1.24 (0.75-2.04) 17% (8.0%-26%) 
BRCA2 Age 19-64 362 1936.2 7 3.62 (1.71-7.65) 3.33 2.10 (0.99-4.47) 5.6% (1.5%-9.8%) 
 Age 65-84 153 618.2 19 30.7 (19.3-49.0) 7.77 2.44 (1.53-3.90) 41% (22%-59%) 
  Overall 447 2554.4 26 10.2 (6.92-15.0) 11.1 2.34 (1.57-3.48) 41% (22%-59%) 










increased by a factor 
of ×1.6 [25]c 
 Age 65-84 149 691.7 8 11.6 (5.79-23.1) 7.34 1.09 (0.54-2.18) 18% (7.1%-28%) 
 Overall 352 2323.3 13 5.60 (3.24-9.68) 10.3 1.26 (0.73-2.19) 18% (7.1%-28%) 
BRCA2 Age 19-64 335 1761.7 5 2.84 (1.17-6.87) 2.58 1.94 (0.80-4.72) 5.5% (0.67%-10%) 
 Age 65-84 141 577.2 15 26.0 (15.5-43.7) 6.12 2.45 (1.46-4.12) 40% (19%-61%) 
  Overall 414 2338.8 20 8.55 (5.51-13.3) 8.70 2.30 (1.47-3.60) 40% (19%-61%) 
All participants until 
1st October 2005, and 
participants from 
centres not recruiting 
to the IMPACT 
screening trial [26] 
after 1st October 
2005 
BRCA1 Age 19-64 115 497.5 0 0.00  1.38 0.00  0%  
 Age 65-84 54 208.3 2 9.60 (2.31-39.9) 3.07 1.05 (0.24-4.55) 11% (2.9%-39%) 
 Overall 147 705.8 2 2.83 (0.69-11.6) 2.72 0.74 (0.18-3.04) 11% (2.9%-39%) 
BRCA2 Age 19-64 113 439.7 3 6.82 (2.11-22.0) 0.67 6.75 (1.98-23.0) 20% (6.6%-50%) 
 Age 65-84 34 108.7 1 9.20 (1.27-66.7) 0.68 1.48 (0.20-10.7) 36% (13%-75%) 
  Overall 134 548.4 4 7.29 (2.69-19.8) 1.12 3.57 (1.29-9.85) 36% (13%-75%) 
Participants from 
centres recruiting to 
the IMPACT screening 
trial [26] after 1st 
October 2005 
BRCA1 Age 19-64 241 1275.8 7 5.49 (2.61-11.5) 1.42 4.93 (2.33-10.4) 14% (6.7%-26%) 
 Age 65-84 120 523.7 7 13.4 (6.43-27.8) 3.52 1.99 (0.95-4.15) 34% (20%-53%) 
 Overall 310 1799.5 14 7.78 (4.63-13.1) 4.94 2.83 (1.67-4.81) 34% (20%-53%) 
BRCA2 Age 19-64 298 1496.4 4 2.67 (1.00-7.17) 1.42 2.81 (1.04-7.60) 7.7% (2.9%-19%) 
 Age 65-84 129 509.5 18 35.3 (21.8-57.2) 3.42 5.27 (3.25-8.54) 62% (44%-80%) 
  Overall 372 2006.0 22 11.0 (7.16-16.8) 4.84 4.54 (2.96-6.99) 62% (44%-80%) 
 
Abbreviations 
CI: confidence interval. SIR: standardised incidence ratio.
a Estimated cumulative prostate cancer risk by the end of each age interval, or age 85. 
b BRCA1: c.68_69delAG and c.5266dupC; BRCA2: c.5946delT. 
c The absolute risks were estimated using a Kaplan-Meier estimator weighted by the inverse of the adjustment factor for men with events. 





Figure 1: Absolute prostate cancer risks for BRCA1 and BRCA2 mutation carriers, with the number at 
risk at each age on the x-axis.  
A: Overall.  
B: Overall, with follow-up initiated six mo after study entry.  
C: By family history.  
D: By family history, with follow-up initiated six mo after study entry.  
E: By the BRCA2 ovarian cancer cluster region (OCCR, wide definition) [2,21].  
F: By the BRCA2 ovarian cancer cluster region (OCCR, wide definition) [2,21], with follow-up initiated 
six mo after study entry. 
Family history was defined as having at least one first- or second-degree relative with a prostate 







Supplementary appendix 1: Full details on the statistical analysis  
 
We prospectively followed the participants from the completion of their baseline questionnaire until 
their age at diagnosis of prostate cancer, age of death, age at the end of follow-up, or age 85, 
whichever occurred first. A diagnosis of another cancer or of prostatic intraepithelial neoplasia were 
not considered as censoring events. In all analyses the event of interest was a prostate cancer 
diagnosis. We calculated the total follow-up time using the reverse Kaplan—Meier method [1]. 
 
We compared the observed prostate cancer incidences in study participants to those expected from 
population incidences (Cancer registration statistics, England, Office for National Statistics, 
https://www.ons.gov.uk/), using standardised incidence ratios (SIR) computed with Poisson 
regression. For this purpose we used age-and-calendar-period specific incidences (available in five-
year age bands for individual years 1998 to 2016). Analyses were carried out separately for BRCA1 
and BRCA2 mutation carriers. To estimate the absolute risks for mutation carriers, we used the 
counting process formulation of the Kaplan—Meier estimator to account for varying ages at study 
entry. Cox regression was used to test for differences in risk between subgroups of mutation carriers 
(e.g. by family history or mutation characteristics). We classified men who had at least one first- or 
second-degree family member diagnosed with PCa as having positive PCa family history, and 
assessed trends in risks with the number of affected first- and second-degree relatives.  
 
Analogously, we followed the participants for prostate-cancer-specific mortality from the 
completion of their baseline questionnaire until their age at death due to prostate cancer, or age at 
death due to other causes, age at the end of follow-up, or age 85. We computed prostate-cancer-
specific standardised mortality ratios (SMR) compared to age-and-calendar-period-specific 
population prostate cancer mortality rates (available in five-year age bands for individual years 1998 
to 2016; Deaths registered in England and Wales, England and Wales, Office for National Statistics, 
https://www.ons.gov.uk/). 
 
To investigate differences in risk by mutation characteristics, we grouped mutations on the basis of 
mutation position within the genes. The grouping was pre-specified, using previously published 
definitions of regions that have demonstrated different associations with PCa risk [2–7]. The 
mutation locations were specified using HGVS nomenclature (http://varnomen.hgvs.org/), using 
cDNA reference sequences NM_007294.3 (BRCA1) and NM_000059.3 (BRCA2) and reference 
genome hg18. In HGVS nomenclature, the nucleotide numbering is from the A of the ATG translation 
initiator codon. For deletions or insertions where the position was uncertain the change was 
assumed to have occurred at the most 3′ position. Specifically for BRCA2, we assessed differences 
between mutations in the central region of the gene, known as the ovarian cancer cluster region 
(OCCR) [2], and mutations outside this region. For this purpose we used both the wide definition 
(c.2831 to c.6401) [2,3,8] and the narrow definition (c.3847 to c.6275) of the OCCR [2,3,8]. Similarly, 
we compared risks for mutations within a recently proposed prostate cancer cluster region (PCCR): 
c.6373 to c.6492 [7], to mutations located outside this region. However, only three men had a 
mutation in this PCCR, and hence we could not assess the differences in risk on the basis of this 





and we assessed the impact of carriers of Ashkenazi founder mutations on the mutation location 
results by excluding this subgroup.   
 
To account for the correlation between male relatives we used sandwich estimators based on 
family-specific clusters for the standard errors in all Poisson and Cox regression models [9]. We used 
the Schoenfeld residuals test to assess the Cox regression proportional hazards assumption. 
 
We assessed the association of BRCA1/2 mutations with clinical subtypes of PCa based on biopsy 
Gleason score (GS), by comparing the observed number of PCa diagnoses by GS subtypes to those 
expected given population GS-specific incidences. The GS-specific incidences were calculated using 
the age-and-calendar-period-specific population distribution of GSs (GS≤6 or ≥7; England, Public 
Health England, available in five-year age bands in three-calendar-year bands for 1995-2016). For 
the SIR calculations, diagnosis of a competing PCa subtype ended the follow-up without an event. To 
estimate absolute risks of these clinical subtypes, we used competing risk estimators [10]. Because 
data on GSs were not available in the EMBRACE study for all PCas, we used multiple imputation to 
avoid omission of PCa events. 
 
Missing values were imputed using Multivariate Imputation by Chained Equations [11], based on the 
following variables: Prostate cancer status, Gleason score, PSA at diagnosis, Clinical stage, Diagnostic 
modality (screening/clinical), Mutation gene (BRCA1/2), Year of birth, Age at study entry, Age at 
follow-up, and Family history (number of affected first- and second-degree relatives). All variables 
were complete for all participants except for Family history, and tumour characteristics for 10 of the 
men with a known PCa. We used polytomous logistic regression to impute categorical variables and 
predictive mean matching for continuous variables. The imputation was repeated 100 times, and for 
the results by GS we present the resulting estimates after pooling the separate estimates calculated 
from each of the 100 repetitions. 
 
For the main analysis, we allowed men with previous non-prostate cancers to be included, did not 
censor for non-prostate cancers during follow-up, and considered follow-up up to the last 
questionnaire if available after the last record linkage. We assessed the impact of these inclusion 
and censoring criteria by excluding men with previous non-prostate cancers, and in separate 
analyses by censoring men at the age of any non-prostate cancers (excluding non-melanoma skin 
cancers), or on 30th June 2016.  
 
The analysis included carriers of missense mutations that have been classified as pathogenic based 
on the ENIGMA criteria (https://enigmaconsortium.org/); since such mutations may be associated 
with different risks than protein truncating mutations, we carried out a sensitivity analysis in which 
we omitted these missense mutations (eight BRCA1 and nine BRCA2 carriers). 
 
Mutation carriers may be offered a different screening and diagnosis regimen than men in the 





detection of indolent PCas shortly after the detection of a mutation, and (2) enhanced screening for 
PCa over an extended period of time. To address this we performed a number of sensitivity analyses 
to assess the potential impact of such differential screening. Firstly, we performed landmark 
analyses where follow-up was initiated six or twelve months after baseline. Second, based on 
previous findings that observed PCa incidences are 1.4-1.9 times higher for men undergoing PSA 
screening at regular intervals as compared to unscreened men [13], we compared the observed PCa 
rates in our sample to population incidences multiplied by adjustment factors of 1.6 and 1.9. To 
obtain corresponding absolute risk estimates, we used weighted Kaplan—Meier estimators with 
bootstrap estimates for the standard errors (1000 repetitions). In this analysis, participants with 
incident PCa where assigned weights proportional to the inverse of the screening adjustment factor. 
Furthermore, in October 2005 the UK-based IMPACT screening trial started recruiting BRCA1/2 
participants [14]. Although the exact overlap between IMPACT and EMBRACE is unclear, we assessed 
PCa risks separately for the follow-up that was potentially overlapping with the IMPACT trial and the 
non-overlapping follow-up. For this, we separately considered the person-time from October 2005 
of participants from centres that recruited to IMPACT, and the person-time of participants from 
IMPACT-recruiting centres before the initiation of IMPACT in addition to the entire person-time of 
participants from non-IMPACT-recruiting centres. 
 
We used R software (version 3.4.4) [15] for the statistical analysis.  
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baseline n Person-years 
Observed 
events 
Incidence rate per 
1000 person-years 
BRCA1      
 0–6 mo 376 181.97 3 16.49 
 6 mo–1 yr 352 172.61 0 0.00 
 1–2 yr 341 337.00 2 5.93 
 2–3 yr 334 302.46 1 3.31 
 3–4 yr 279 262.75 5 19.03 
 4–5 yr 251 240.08 1 4.17 
 5–10 yr 231 725.81 4 5.51 
 10–15 yr 94 247.95 0 0.00 
BRCA2      
 0–6 mo 447 215.59 6 27.83 
 6 mo–1 yr 414 202.69 3 14.80 
 1–2 yr 400 389.08 4 10.28 
 2–3 yr 381 332.76 4 12.02 
 3–4 yr 303 278.21 5 17.97 
 4–5 yr 257 249.17 0 0.00 
 5–10 yr 241 710.77 3 4.22 






Supplementary table 2: Published age-specific absolute prostate cancer risk estimates and 95% confidence intervals. 
 
Gene Publication Study design Setting Age         
    45 50 55 60 65 70 75 80 85 
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